December 2, 2011—Witnessesses testifying before a U.S. House subcommittee largely agreed that Medicare pharmacy reimbursement is one of the core reasons behind critical shortages of generic injectable drugs, but they differed over whether 340B discounts are a factor.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)